Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.

× No keyword cloud information.

11 in total

1. Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors: Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal: Infect Immun Date: 2002-12 Impact factor: 3.441

Review 2. Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors: Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal: Ther Adv Hematol Date: 2015-12

Review 3. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors: R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal: Springer Semin Immunopathol Date: 1998

Review 4. The complexity of the Epstein-Barr virus infection in humans.

Authors: E Klein
Journal: Pathol Oncol Res Date: 1998 Impact factor: 3.201

Review 5. Developing T-cell therapies for lymphoma without receptor engineering.

Authors: Melanie Grant; Catherine M Bollard
Journal: Blood Adv Date: 2017-12-08

Review 6. Developing T-cell therapies for lymphoma without receptor engineering.

Authors: Melanie Grant; Catherine M Bollard
Journal: Hematology Am Soc Hematol Educ Program Date: 2017-12-08

Review 7. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.

Authors: Jan Storek; Michelle Geddes; Faisal Khan; Bertrand Huard; Claudine Helg; Yves Chalandon; Jakob Passweg; Eddy Roosnek
Journal: Semin Immunopathol Date: 2008-10-24 Impact factor: 9.623

Review 8. Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Authors: Melanie L Grant; Catherine M Bollard
Journal: Blood Rev Date: 2017-11-27 Impact factor: 8.250

Review 9. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra.

Authors: Francesca Montanari; Manuela Orjuela-Grimm
Journal: Curr Hematol Malig Rep Date: 2021-02-05 Impact factor: 3.952

10. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.

Authors: Lauren P McLaughlin; Rayne Rouce; Stephen Gottschalk; Vicky Torrano; George Carrum; Meng-Fen Wu; Fahmida Hoq; Bambi Grilley; Andrea M Marcogliese; Patrick J Hanley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal: Blood Date: 2018-09-27 Impact factor: 25.476